The stock has a 36-month beta value of 2.11. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 5 as “hold,” and 1 as “sell.”
The public float for FULC is 46.61M, and at present, short sellers hold a 10.04% of that float. On November 27, 2024, the average trading volume of FULC was 1.65M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
FULC) stock’s latest price update
Fulcrum Therapeutics Inc (NASDAQ: FULC) has experienced a rise in its stock price by 13.24 compared to its previous closing price of 3.55. However, the company has seen a gain of 34.45% in its stock price over the last five trading days. globenewswire.com reported 2024-11-26 that CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences:
FULC’s Market Performance
Fulcrum Therapeutics Inc (FULC) has experienced a 34.45% rise in stock performance for the past week, with a 24.07% rise in the past month, and a -54.00% drop in the past quarter. The volatility ratio for the week is 7.78%, and the volatility levels for the past 30 days are at 6.72% for FULC. The simple moving average for the last 20 days is 20.40% for FULC’s stock, with a simple moving average of -43.08% for the last 200 days.
Analysts’ Opinion of FULC
Many brokerage firms have already submitted their reports for FULC stocks, with H.C. Wainwright repeating the rating for FULC by listing it as a “Neutral.” The predicted price for FULC in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on September 13, 2024 of the current year 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to FULC, setting the target price at $4 in the report published on September 12th of the current year.
FULC Trading at 17.38% from the 50-Day Moving Average
After a stumble in the market that brought FULC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.66% of loss for the given period.
Volatility was left at 6.72%, however, over the last 30 days, the volatility rate increased by 7.78%, as shares surge +24.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.01% upper at present.
During the last 5 trading sessions, FULC rose by +34.62%, which changed the moving average for the period of 200-days by -55.03% in comparison to the 20-day moving average, which settled at $3.34. In addition, Fulcrum Therapeutics Inc saw -40.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FULC starting from Tourangeau Greg, who sale 236 shares at the price of $7.76 back on May 07 ’24. After this action, Tourangeau Greg now owns 11,571 shares of Fulcrum Therapeutics Inc, valued at $1,831 using the latest closing price.
Tourangeau Greg, the Vice President, Finance of Fulcrum Therapeutics Inc, sale 4,884 shares at $11.72 during a trade that took place back on Mar 08 ’24, which means that Tourangeau Greg is holding 11,807 shares at $57,219 based on the most recent closing price.
Stock Fundamentals for FULC
Current profitability levels for the company are sitting at:
- -0.38 for the present operating margin
- 0.77 for the gross margin
The net margin for Fulcrum Therapeutics Inc stands at -0.22. The total capital return value is set at -0.12. Equity return is now at value -6.99, with -6.42 for asset returns.
Currently, EBITDA for the company is -108.49 million with net debt to EBITDA at 2.43. When we switch over and look at the enterprise to sales, we see a ratio of 1.9. The receivables turnover for the company is 22.12for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.44.
Conclusion
To sum up, Fulcrum Therapeutics Inc (FULC) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
